Prof. Xiaoqing Liu 刘晓晴
Chief Physician, Professor
Department of Medical Oncology, Chinese PLA General Hospital (301 Hospital), First Medical Center, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of lung cancer, including chemotherapy, molecular targeted therapy, and immunotherapy. Focuses on predictive and individualized therapy, as well as domestic and international clinical trials for new lung cancer drugs.
Dr. Liu is a Chief Physician and Professor at the Chinese PLA General Hospital. A doctoral supervisor, Dr. Liu leads the Lung Cancer Multidisciplinary Treatment Center. Research focuses on radiotherapy, chemotherapy, and biological targeted therapy for lung cancer. Dr. Liu has led national research projects, published over 100 papers, and contributed to multiple national clinical guidelines and expert consensuses.
Professional roles
- Vice Chair, Small Cell Lung Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Precision Medicine and Tumor Rehabilitation Professional Committee
- Vice Chair, Medical Oncology Branch, China International Exchange and Promotion Association for Medical and Healthcare
Name order: in Chinese the family name comes first (Liu Xiaoqing). Papers usually list the name as Xiaoqing Liu or Liu X.
Selected publications
39 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Proteomics, 2024 (senior author): Correlation between small-cell lung cancer serum protein/peptides determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemotherapy efficacy. PubMed 38764042
- Quant Imaging Med Surg, 2023 (senior author): Artificial intelligence versus radiologist in the accuracy of fracture detection based on computed tomography images: a multi-dimensional, multi-region analysis. PubMed 37869340
- Thorac Cancer, 2023 (senior author): Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC. PubMed 37265111
- Thorac Cancer, 2022 (senior author): Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. PubMed 35560808
- Thorac Cancer, 2020 (senior author): CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo. PubMed 32368855
- Cancer Manag Res, 2020 (senior author): Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study. PubMed 32494205
- Mol Med Rep, 2020 (senior author): Exploratory study on application of MALDI‑TOF‑MS to detect serum and urine peptides related to small cell lung carcinoma. PubMed 31746355
- Thorac Cancer, 2020 (senior author): Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy. PubMed 31691525
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion